Zacks Investment Research cut shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a research note released on Tuesday morning.

According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “

A number of other brokerages have also recently issued reports on AQST. Wedbush assumed coverage on shares of Aquestive Therapeutics in a report on Wednesday, September 12th. They set an outperform rating and a $33.00 price objective for the company. Royal Bank of Canada set a $24.00 price objective on shares of Aquestive Therapeutics and gave the company a buy rating in a report on Wednesday, November 7th. JMP Securities assumed coverage on shares of Aquestive Therapeutics in a report on Monday, August 20th. They set an outperform rating and a $29.00 price objective for the company. Finally, BMO Capital Markets assumed coverage on shares of Aquestive Therapeutics in a report on Monday, August 20th. They set an outperform rating for the company. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Aquestive Therapeutics has an average rating of Buy and a consensus target price of $27.67.

Shares of NASDAQ AQST opened at $8.25 on Tuesday. Aquestive Therapeutics has a 1 year low of $7.47 and a 1 year high of $20.70. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.63 and a quick ratio of 3.42.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.15). The firm had revenue of $13.27 million for the quarter, compared to analysts’ expectations of $14.75 million. As a group, equities analysts expect that Aquestive Therapeutics will post -1 EPS for the current year.

In other Aquestive Therapeutics news, CEO Keith J. Kendall acquired 7,950 shares of Aquestive Therapeutics stock in a transaction dated Friday, November 23rd. The stock was purchased at an average cost of $10.10 per share, for a total transaction of $80,295.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO John T. Maxwell acquired 5,000 shares of Aquestive Therapeutics stock in a transaction dated Thursday, December 6th. The shares were acquired at an average price of $8.87 per share, with a total value of $44,350.00. The disclosure for this purchase can be found here. Insiders have bought 25,650 shares of company stock valued at $249,931 over the last quarter.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Crestline Management LP bought a new position in shares of Aquestive Therapeutics during the third quarter valued at about $201,422,000. Perceptive Advisors LLC bought a new position in shares of Aquestive Therapeutics during the third quarter valued at about $20,137,000. Alliancebernstein L.P. bought a new position in shares of Aquestive Therapeutics during the third quarter valued at about $14,323,000. BlackRock Inc. bought a new position in shares of Aquestive Therapeutics during the third quarter valued at about $8,254,000. Finally, Vanguard Group Inc. bought a new position in shares of Aquestive Therapeutics during the third quarter valued at about $8,055,000. 64.49% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Featured Story: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.